Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
复制标题
DOI：
10.1002/cac2.12136
复制
发表时间：
2021
影响因子：
16.2
通讯作者：
Zhang Zhi-yuan
中科院分区：
文献类型：
--
作者：
Ju Wu-tong;Liu Ying;Wang Li-zhen;Li Jiang;Ren Guo-xing;Sun Jian;Tu Wen-yong;Hu Yong-jie;Ji Tong;Yang Wen-jun;Li Jun;He Yue;Wang Yan-an;Zhang Chen-ping;Zhong Lai-ping;Zhang Zhi-yuan
